RDIF Rejects Unreliable Vaccine Technologies Due to Risks Exposed by AstraZeneca's Case

RDIF Rejects Unreliable Vaccine Technologies Due to Risks Exposed by AstraZeneca's Case

"We've drawn up a series of plan packages, including medical consent forms, side-effects monitoring plans, rescuing plans, compensation plans, to make sure the emergency use is well regulated and monitored", Zheng Zhongwei, head of China's coronavirus vaccine development task force told the official media here last month.

AstraZeneca announced the suspension of its phase-three trial on Tuesday, after one of the trial participants suffered a "serious adverse reaction".

All follow-up appointments with people already vaccinated continued as normal during the week's pause, the university said.

Health Secretary Matt Hancock welcomed the news that the trials would resume.

"But this [a trial being paused] is not the first time it's happened, it happens quite frequently and we shouldn't be too perturbed, in fact we should be reassured because if these sorts of things are being picked up and monitored, it actually shows us that the proper channels, the proper processes are being followed - this is not a rush job".

"We must all hope that there are no future events and that the vaccine proves both safe and effective".

AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials.

On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow the review of safety data by independent committees, and worldwide regulators.

The statement came in response to AstraZeneca's announcement that vaccine trials have resumed in the UK.

The disrupted clinical trials of the United Kingdom coronavirus vaccine by the AstraZeneca pharmaceutical company have exposed the risks associated with the excessive reliance upon new unverified technologies, an approach that Russia finds unacceptable, Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), said on Saturday. The company didn't immediately respond to a question on when the trials would resume in the USA, which officially began late last month, or elsewhere.

The study participant in late-stage testing reported symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord, said company spokesman Matthew Kent.

The pharma giant also stated that it had "voluntarily paused" the trial.

The vaccines exhibited successful results during trials in other countries, she added.

Pharmaceutical company Astra Zeneca said on Saturday it would continue its experiment to develop a coronavirus vaccine after the company received permission from the British authorities to do so. On May 21, the U.S. Department of Health and Human Services said it would provide the drug company up to $1.2 billion for at least 300 million doses of the vaccine.

Related Articles